[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 0.9% 56.00 55.00 57.00 56.00 55.50 55.50 1,971,788 14:31:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 30.1 3.3 2.7 20.4 70

Venture Life Share Discussion Threads

Showing 35801 to 35823 of 36000 messages
Chat Pages: 1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  1429  Older
DateSubjectAuthorDiscuss
05/5/2021
10:27
These imminent acquisitions. When?
farnesbarnes
03/5/2021
08:24
Cheers Whatja. From the Times - this appears to be a second study which has found the benefit of using mouthwash in reducing the risk of catching COVID-19: Https://www.thetimes.co.uk/article/colds-are-even-more-common-as-covid-lockdown-eases-0vb8n2h9s "Scientists believe the risk of catching and spreading coronavirus can be slashed by mouthwash after laboratory tests. The study, conducted by York and Scarborough Teaching Hospitals NHS Foundation Trust and Public Health England, has been published in the Journal of General Virology. Researchers will use the best-performing mouthwashes in a controlled clinical trial."
rivaldo
27/4/2021
14:44
Rivaldo I think you need to rinse daily to keep the bacterial load down. Don’t swallow to maintain the good gut bacteria. Bacteria found in the brains of alzheimer patients strongly correlate with bacteria found in the mouth. These bacteria are also present in the blood of Alzheimer’s patients and those with advanced gum disease. The hypothesis is that the bacteria enter the blood stream via damaged gums. Keep taking the mouthwash.
whatja
27/4/2021
14:09
Hpcg, I'm now a convert to mouthwash. I only started using it last year, and I have to say that it worked really well whenever I felt an infection or a little tooth pain. I gather you shouldn't use it all the time as this would get rid of "good" bacteria, but two or three days a week is presumably fine.
rivaldo
26/4/2021
22:48
Rivaldo - I gargle with a mouth wash when I have an infection. As per the article the idea is to disable as much virus as possible before it can get into a cell. Poor mouth hygiene is associated with brain diseases too - its a root into the body for infection.
hpcg
15/4/2021
21:33
I have updated my valuation model for the final results. Now getting 111.7p. Still plenty to go for here, in my opinion.
effortless cool
14/4/2021
22:53
Indeed - the shareholder list is now mightily impressive. This list now accounts for over 66% of the shares in issue: Shareholder Number of shares held % issued share capital Slater Investments 19,121,431 15.2% BlackRock 10,287,191 8.2% BGF Investment Management Limited 9,581,824 7.6% Hargreaves Lansdown 7,470,972 5.9% Directors 6,440,937 5.1% River & Mercantile Asset Management LLP 6,437,200 5.1% JO Hambro Capital Management 5,555,000 4.4% Close Brother Asset Management 5,538,410 4.4% Stonehage Fleming 5,093,438 4.0% Octopus Investments 4,015,000 3.2% Chelverton Asset Management 3,778,000 3.0%
rivaldo
12/4/2021
15:22
Let's hope this slow edging up bodes well for some M&A action reports soon! DYOR
qs99
07/4/2021
14:36
The annual report reads well, especially the risk section. I think buying in (as I just have) below the placing price limits downside. Bottom of the retrace at 80p or so looks well in.
hpcg
03/4/2021
12:08
The Q&A is now available to view on the IMC website.
sharw
02/4/2021
20:01
https://www.fool.co.uk/investing/2021/03/31/2-small-cap-uk-shares-that-could-outperform-the-ftse-100/
tole
30/3/2021
10:43
The recording of the presentation is now available on IMC. The Q&A is not yet there. Basically they ran out of time for Q&A but it sounded as if there were several on acquisitions.
sharw
29/3/2021
16:48
Thank you EC
shanklin
29/3/2021
16:17
No, they didn't cover that and it was not one of the pre-submitted questions (there was no time to cover questions submitted during the presentation, although we were promised written answers later).
effortless cool
29/3/2021
15:26
Hi EC Was there any commentary please on why the directors sold so many shares at the time of the placing? Presumably they did not say it was because they thought the share price was far too high :-)
shanklin
29/3/2021
14:47
It was an interesting presentation, giving insights into the business beyond those that can be gleaned from the published results. On acquisitions, they didn't really explain why there has been such a delay from the fundraising to actually completing a new acquisition. However, it was very clear that 'buy and build' is their core business strategy, and more acquisitions will certainly come. Related to this, there was an useful slide showing the spare manufacturing capacity they have at present and how they can double current capacity with further investment of £10m.
effortless cool
29/3/2021
14:24
I thought it looked good. A £50 million debt facility is being prepared and will be completed soon. They suggested a 50% debt:50% cash approach to M&A. Looks to me that they may be eyeing up some bigger targets. Maybe that is why M&A appears to be taking longer than expected. They have many opportunities they are screening. Production facilities have multiple routes to expansion. Last years expansion gives them almost 50% free capacity on last years volumes.
thedudie
29/3/2021
14:12
Anyone listen in? Views please? Stuck on zoom calls! Thanks QS99
qs99
29/3/2021
12:31
Just a reminder that the Investor Meet video call starts at 1pm with the CEO, CFO and CCO: Https://www.investormeetcompany.com/
simon gordon
29/3/2021
12:28
Nice start to the week. QS99, Cenkos don't have a target price. However, they see an EV/EBITDA ration of only 9.3 for the current year, which is above average/healthy, along with the ex-cash P/E of only 12.9.
rivaldo
26/3/2021
08:27
Thanks Riv.....does it give a TP? No worries if not. I'm more EV/EBITDA ratio value hunter really.....but it is a strong note IMO and thanks for sharing. Good they have bolstered the M&A team. Mind you in my day at a PLC we managed to do plenty in one year with a minimal team (me!)....so VLG are behind the curve on timing IMO still.... DYOR
qs99
25/3/2021
23:12
Here's Cenkos' summary today for the record - encouraging to see their confidence that an acquisition will be completed in the "near-term": "Venture Life Group Plc Outstanding year Venture Life Group has delivered an outstanding year with revenues up c50% and adjusted EBITDA up over 100%. Revenue growth was delivered both organically and via M&A, and across both the Venture Life brands and the Customer brands divisions. Revenue growth was matched by margin expansion, with gross margin up over 300bps and adjusted EBITDA margin above 20% for the first time. The group closed 2020 with a strong balance sheet able to support M&A. We believe Venture Life is entering 2021 in an exceptionally strong position with numerous organic growth opportunities and the financial capacity to complete significant acquisitions through the year. We reiterate our Buy recommendation. Venture Life brands– Venture Life brands revenues grew over 120% in 2020A, supported by both organic and M&A growth. Significantly, Dentyl revenues were up 80% and the company has resumed shipments of this product to its Chinese partner. PharmaSource contributed £2.8m of revenues and the new brand DISINPLUS contributed £3.6m. Customer brands– Revenues from the manufacture of customer brands were also up 12% in the year, supported by new and existing customers. Through the year, capacity at the manufacturing site was expanded providing scope for future growth in support of the group’s organic and acquisition strategies. M&A – Whilst the Group has not yet completed on any of the three potential acquisition targets discussed with the recent equity raise, we remain confident that at least one of these deals will be completed in the near-term. The raise has also enabled Venture Life to pursue other promising M&A assets and the company has added resources to bolster is M&A capabilities and increase pipeline development. Profitability– We believe 2020 demonstrated the significant operational leverage capacity within the group. Gross margin was up +300bps supported by favourable mix, manufacturing efficiency and higher margin acquired products. The adjusted EBITDA margin moved above 20% for the first time. Investment thesis – We believe Venture Life is in an exceptionally strong position at the start of 2021. We see organic growth opportunities in both divisions while the balance sheet strength and available debt financing is expected to support management’s M&A ambitions through the year. We remain Buyers of the stock."
rivaldo
25/3/2021
20:41
You can't resist but I'll leave it there
davr0s
Chat Pages: 1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  1429  Older
ADVFN Advertorial
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210927 20:04:52